ClinicalTrials.gg
Not yet recruitingNCT07790783Updated Aug 27, 2026

Phase 1 Clinical Study of GenSci164 Injection

A Phase 1 interventional study of GenSci164 Injection and Placebo in Healthy Adult Trial Participants, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a single-center, randomized, double-blind, placebo-controlled, single-dose escalation Phase 1 clinical study to evaluate the safety, tolerability, PK profile, PD profile, and immunogenicity of GenSci164 after a single subcutaneous injection in healthy adult participants in China.

02

Conditions studied

  • Healthy Adult Trial Participants

Keywords

  • Healthy Volunteers
  • GenSci164
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 18 and 55 years (inclusive) at the time of signing the form (ICF).
  2. Body weight ≥ 50 kg for males and ≥ 45 kg for females at screening, and (BMI) between 18 and 30 kg/m2 (inclusive).
  3. No abnormalities in medical history, physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function, etc.), (ECG), and pulmonary imaging tests, or values outside the normal reference range considered not clinically significant by the investigator during the screening period or before randomization.
  4. Men and women of (WOCBP) must agree to use highly effective measures from the screening period to 3 months after the end of the study, and not plan to father a child (for men) or become pregnant (for women) from signing the ICF to 3 months after the end of the study. WOCBP must have a pregnancy test result within the normal range at screening or before randomization, and must not be breastfeeding. Women not of childbearing potential are those who are permanently sterilized (e.g., hysterectomy) or .
  5. Able to understand the study procedures, voluntarily participate in the study, provide written informed consent, comply with all study requirements, and complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to any component of the GenSci164 injection formulation, or a history of severe allergic reactions to any drugs, compounds, foods, or other substances, or a history of allergic diathesis.
  2. The proposed injection site has tattoos, sunburn, scarring, or other factors that might interfere with the evaluation of the injection site.
  3. History or presence of serious metabolic, allergic, dermatological, hepatic, renal, hematological, cardiovascular, gastrointestinal, psychiatric, neurological, respiratory, and/or other significant medical conditions that, in the investigator's opinion, may affect the evaluation of this study.
  4. Known confirmed history of .
  5. Participants with a history of epileptic seizures or an increased risk of epileptic seizures, or participants with a recent history (within 6 months prior to screening) of head trauma resulting in loss of consciousness or concussion.
  6. History of psychiatric or neurological disorders, or limited ability to perform normal activities, or cognitive impairment.
  7. Severe trauma or major surgery within 12 months prior to screening, or gastrointestinal diseases within 3 months prior to screening that could affect the absorption, distribution, metabolism, excretion, or safety evaluation of the IMP.
  8. abnormal vital signs at screening (and remaining abnormal and clinically significant upon repeat measurement as determined by the investigator), including, but not limited to, systolic blood pressure ≥ 140 mmHg or \< 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or \< 50 mmHg.
  9. Positive surface antigen (HBsAg), positive virus antibody (HCV-Ab), preliminary positive antigen/antibody (HIV Ag/Ab) test, or positive Treponema pallidum antibody (TP-Ab) at screening.
  10. Clinically significant abnormal findings on chest X-ray.
  11. As judged by the investigator, participants who are currently using any medications (including over-the-counter [OTC] drugs, herbal, or homeopathic preparations) that cannot be discontinued or avoided from 4 weeks prior to randomization (or the time period defined below) through 1 month after randomization.
  12. For female participants, use of hormone replacement therapy within 3 months prior to randomization.
  13. Participation in any clinical trial of an drug (including investigational vaccines) and receipt of the investigational drug within 3 months or within 5 terminal elimination half-lives (whichever is longer) prior to screening; participation in any clinical trial of a medical device within 3 months prior to screening (excluding screening failures); currently participating in other clinical trials.
  14. Average weekly alcohol consumption exceeding the limit within 6 months prior to randomization [defined as an average weekly intake of > 14 units, where 1 unit of alcohol = 150 mL of wine, or 360 mL of beer, or 45 mL of spirits].
  15. Average daily smoking of ≥ 5 cigarettes within 6 months prior to randomization, and/or unwillingness to quit smoking during the study, and/or positive nicotine test.
  16. Positive alcohol breath test, or history of drug abuse, or use of soft drugs (e.g., marijuana) within 3 months prior to screening, or use of hard drugs (e.g., cocaine and ketamine) within 1 year prior to screening, or positive drug screening result [including but not limited to morphine, ketamine, 3,4-methylenedioxyamphetamine, methamphetamine, tetrahydrocannabinol (THC), cocaine].
  17. Blood donation or blood loss of ≥ 400 mL, or receipt of blood products within 3 months prior to randomization; poor peripheral venous access, or inability to tolerate blood collection due to physical condition.
  18. Study staff, site personnel, or other persons directly involved in the execution of the protocol.
  19. Any other medical condition that, in the investigator's opinion, would impair the participant's ability to tolerate the IMP or to continue with the procedures required by this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    GenSci164 Injection

    Drug: GenSci164 Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugGenSci164 Injection

    6 dose cohorts

  • DrugPlacebo

    6 dose cohorts

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) assessed by CTCAE v6.0

    Adverse events (AEs)will be identified and collected from physical examination, vital signs, laboratory tests, 12-lead ECG, and other clinical assessments from Day 1 dosing up to 113 days post dose. Severity will be graded per NCI CTCAE v6.0. AEs will be summarized by number and percentage of affected participants, and further categorized by System Organ Class (SOC), Preferred Term (PT), and severity grade.

    Time frame: From dosing on Day 1 up to 113 days post dose

Secondary outcomes

  1. Area under the concentration-time curve (AUC0-t, AUC0-∞)of "SZ08330849/PEP072 complex, total SZ08330849 antibody, and active PEP072 (free PEP072 and PEP072-albumin conjugate)"

    Time frame: From dosing on Day 1 up to 113 days post dose

  2. maximum concentration (Cmax)

    Time frame: From dosing on Day 1 up to 113 days post dose

  3. time to maximum concentration (Tmax)

    Time frame: From dosing on Day 1 up to 113 days post dose

  4. half-life (t1/2)

    Time frame: From dosing on Day 1 up to 113 days post dose

  5. Apparent clearance (CL/F)

    Time frame: From dosing on Day 1 up to 113 days post dose

  6. Apparent volume of distribution (Vz/F)

    Time frame: From dosing on Day 1 up to 113 days post dose

  7. Incidence of anti-drug antibody (ADA) and neutralizing antibody (NAb) positivity and ADA titer.

    Time frame: From dosing on Day 1 up to 113 days post dose

Other outcomes

  1. Albumin-corrected serum calcium levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  2. Serum parathyroid hormone [PTH (1-84)] levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  3. 24-hour urine calcium levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  4. urine phosphate levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  5. urine magnesium levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  6. fractional excretion of calcium (FeCa) levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  7. calcium:creatinine ratio levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  8. Procollagen type 1 N-terminal propeptide (P1NP) levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  9. C-terminal telopeptide of type 1 collagen (CTx) levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

  10. Bone-specific phosphatases (BSAP) levels and changes from baseline

    Time frame: From dosing on Day 1 up to 113 days post dose

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Oct 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 27, 2026
StartEst.
Aug 24, 2026
Primary completionEst.
Oct 25, 2027
CompletionEst.
Feb 28, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07790783
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Aug 24, 2026 (estimated)
Primary completion
Oct 25, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Qingjiang Ni
Contact
niqingjiang@genscigroup.com
+86 17712631723

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion